OBJECTIVE: To demonstrate the safety and efficacy of photoselective vaporization of the prostate in alleviating refractory lower urinary tract symptoms in prostate cancer patients who are managed with active surveillance and to explore the association of this procedure with prostate specific antigen (PSA) levels and cancer progression rates. METHODS: Between 2008-2018, active surveillance patients who had refractory symptoms and needed surgery were studied. Perioperative functional variables were collected and analyzed. Disease progression was defined as an upgrade or upstage on surveillance biopsies or multiparametric prostate magnetic resonance imaging. Mean postop scores were estimated using locally-weighted methods. The risk of progression was reported using Kaplan-Meier's method. RESULTS: Seventy-one patients were included in the study. The median age was 68 years and the median surveillance time before surgery was 4 years. At 12 months, there were substantial improvements in the mean International Prostate Symptom Score (18-5.9), maximum flow rate (6.8-14 mL/s), postvoid residual (240-73mL), PSA (8.1-5.2 ng/mL), and prostate volume (85-57mL). At 30-days, only 2 patients with grade-III complications. Late consequences included tissue regrowth in 4 and urethral stricture (requiring a single dilation) in 3 patients. PSA levels decreased by 36% at 12 months postoperatively. With a median follow-up of 3.7 years, 7 men progressed and received radical treatment. At 3 years, the probability of remaining on surveillance was 93% (95% CI 87%- 100%). CONCLUSION: Photoselective vaporization of the prostate offers substantial relief of symptoms in active surveillance patients with refractory symptoms, without adverse effects on disease progression rates.
OBJECTIVE: To demonstrate the safety and efficacy of photoselective vaporization of the prostate in alleviating refractory lower urinary tract symptoms in prostate cancer patients who are managed with active surveillance and to explore the association of this procedure with prostate specific antigen (PSA) levels and cancer progression rates. METHODS: Between 2008-2018, active surveillance patients who had refractory symptoms and needed surgery were studied. Perioperative functional variables were collected and analyzed. Disease progression was defined as an upgrade or upstage on surveillance biopsies or multiparametric prostate magnetic resonance imaging. Mean postop scores were estimated using locally-weighted methods. The risk of progression was reported using Kaplan-Meier's method. RESULTS: Seventy-one patients were included in the study. The median age was 68 years and the median surveillance time before surgery was 4 years. At 12 months, there were substantial improvements in the mean International Prostate Symptom Score (18-5.9), maximum flow rate (6.8-14 mL/s), postvoid residual (240-73mL), PSA (8.1-5.2 ng/mL), and prostate volume (85-57mL). At 30-days, only 2 patients with grade-III complications. Late consequences included tissue regrowth in 4 and urethral stricture (requiring a single dilation) in 3 patients. PSA levels decreased by 36% at 12 months postoperatively. With a median follow-up of 3.7 years, 7 men progressed and received radical treatment. At 3 years, the probability of remaining on surveillance was 93% (95% CI 87%- 100%). CONCLUSION: Photoselective vaporization of the prostate offers substantial relief of symptoms in active surveillance patients with refractory symptoms, without adverse effects on disease progression rates.
Authors: Lars Budäus; Michel Bolla; Alberto Bossi; Cesare Cozzarini; Juanita Crook; Anders Widmark; Thomas Wiegel Journal: Eur Urol Date: 2011-10-06 Impact factor: 20.096
Authors: Brandon A Mahal; Santino Butler; Idalid Franco; Daniel E Spratt; Timothy R Rebbeck; Anthony V D'Amico; Paul L Nguyen Journal: JAMA Date: 2019-02-19 Impact factor: 56.272
Authors: Carlos Capitán; Cristina Blázquez; M Dolores Martin; Virginia Hernández; Enrique de la Peña; Carlos Llorente Journal: Eur Urol Date: 2011-06-01 Impact factor: 20.096
Authors: Stijn Roemeling; Monique J Roobol; Stijn H de Vries; Tineke Wolters; Claartje Gosselaar; Geert J L H van Leenders; Fritz H Schröder Journal: Eur Urol Date: 2006-12-05 Impact factor: 20.096
Authors: Jean-Nicolas Cornu; Sascha Ahyai; Alexander Bachmann; Jean de la Rosette; Peter Gilling; Christian Gratzke; Kevin McVary; Giacomo Novara; Henry Woo; Stephan Madersbacher Journal: Eur Urol Date: 2014-06-25 Impact factor: 20.096
Authors: Serban Negoita; Eric J Feuer; Angela Mariotto; Kathleen A Cronin; Valentina I Petkov; Sarah K Hussey; Vicki Benard; S Jane Henley; Robert N Anderson; Stacey Fedewa; Recinda L Sherman; Betsy A Kohler; Barbara J Dearmon; Andrew J Lake; Jiemin Ma; Lisa C Richardson; Ahmedin Jemal; Lynne Penberthy Journal: Cancer Date: 2018-05-22 Impact factor: 6.860